Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells
Innovative Medicines & Omics · 16.03.2026 · 3 (4) · 025520080
DOI: 10.36922/imo025520080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovative Medicines & Omics, online erschienen am 16.03.2026. Verfasst von Shogo Ozawa.
Abstract (Originalsprache)
Cancer stem cells (CSCs) express specific antigens associated with stemness. CSCs derived from solid tumors are resistant to various anticancer agents. Given that the spectrum of drug resistance in CSCs is not well understood, literature searches using various keyword combinations were performed to investigate whether CSCs residing in solid cancers are innately resistant to both lipophilic (e.g., P-glycoprotein substrates) and hydrophilic (e.g., non-P-glycoprotein substrates) substances. Current literature suggests that solid CSCs are more likely to acquire multidrug resistance; that is, they are significantly more likely to resist a wide variety of low-molecular-weight anticancer drugs regardless of whether these drugs are P-glycoprotein substrates. The present review further delineates emerging evidence on the use of nanomedicine to eradicate CSCs.
Zitieren
APA
Ozawa, S. (2026). Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells. Innovative Medicines & Omics, 3(4), 025520080. https://doi.org/10.36922/imo025520080
Vancouver
Ozawa S. Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells. Innovative Medicines & Omics. 2026;3(4):025520080. doi:10.36922/imo025520080
BibTeX
@article{Ozawa2026,
author = {Ozawa, Shogo},
title = {Formulation of nanomedicine as a therapeutic candidate for multidrug-resistant cancer stem cells},
journal = {Innovative Medicines & Omics},
year = {2026},
volume = {3},
number = {4},
pages = {025520080},
doi = {10.36922/imo025520080}
}
EUVIMED